Apixaban Management for Basal Cell Carcinoma Excision
For a patient on apixaban (Eliquis) undergoing excision of basal cell carcinoma, hold the medication for 24 hours before the procedure (skip the dose on the day of surgery).
Rationale Based on Bleeding Risk Classification
Basal cell carcinoma excision is a low bleeding risk dermatologic procedure where any bleeding would be superficial, easily controlled, and non-critical in location 1. The FDA label for Eliquis specifically states that the medication should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding 2.
Evidence-Based Approach
The most recent high-quality evidence comes from the PAUSE trial (2018), which prospectively studied 3,007 patients with atrial fibrillation on DOACs 3. For low-to-moderate bleeding risk procedures, the standardized protocol involved:
- Stopping apixaban 1 day before the procedure (skip 2 doses)
- Resuming 1 day after the procedure (at least 24 hours post-procedure)
This approach resulted in excellent outcomes:
- Arterial thromboembolism rate: 0.16% (95% CI: 0-0.48)
- Major bleeding rate: 1.35% (95% CI: 0-2.0)
Pharmacokinetic Justification
Apixaban has a half-life of 7-8 hours 1. A 24-hour interruption corresponds to approximately 3 half-lives, which reduces anticoagulant effect to 3-6% of steady-state levels 1. This minimal residual effect is acceptable for low bleeding risk procedures.
A 2022 prospective study confirmed that 94% of patients achieved apixaban concentrations ≤30 ng/mL (clinically insignificant anticoagulation) when the medication was held for at least 48 hours 4. For a simple dermatologic procedure, even shorter interruption is safe.
Specific Management Protocol
Preoperative Management
- Last dose of apixaban: Morning of the day before surgery
- No bridging anticoagulation needed 2
- No routine coagulation testing required for this low-risk procedure
Renal Function Considerations
- Normal renal function (CrCl ≥50 mL/min): 24-hour hold is sufficient 1
- Moderate renal impairment (CrCl 30-50 mL/min): Consider extending to 48 hours (2 days before surgery, skip 4 doses) 1
Postoperative Resumption
- Resume apixaban 24 hours after the procedure once adequate hemostasis is established 1, 2
- Resume at full dose (5 mg twice daily) - no dose reduction needed 1
Important Clinical Caveats
Do NOT hold apixaban longer than necessary - the 2014 Canadian Cardiovascular Society guidelines note that most minor dermatologic procedures can be safely performed while continuing anticoagulation 5. However, given the ease of local hemostasis control with skin procedures, a brief 24-hour interruption provides an extra margin of safety without significantly increasing thrombotic risk.
Avoid common pitfalls:
- Do not use heparin bridging - this is unnecessary and increases bleeding risk 3
- Do not extend the interruption beyond 48 hours unless there are specific concerns about renal function
- Ensure the patient understands to resume apixaban the day after surgery, not immediately after
The 2024 JAMA review confirms this standardized approach results in thromboembolism rates of 0.2-0.4% and major bleeding rates of 1-2%, which are acceptably low 6.